Certain activity patterns in genes responsible for producing spleen tyrosine kinases can help predict which melanoma patients are more likely to experience severe side effects from immunotherapy treatments(1^✔ ✔Trusted Source
Tyrosine-protein kinase SYK-related gene signature in baseline immune cells associated with adjuvant immunotherapy-induced immune-related adverse events in melanoma

Go to source

).

Predicting Severe Side Effects in Melanoma Immunotherapy through Gene Activity Patterns

Led by researchers at NYU Langone Health and its Perlmutter Cancer Center, this research focused on checkpoint inhibitors, drugs that have become essential in melanoma treatment over the last decade. Melanoma, one of the deadliest forms of skin cancer, causes nearly 10,000 deaths in the U.S. each year.

These drugs work by blocking molecules on the surface of immune T cells that typically prevent them from attacking cancer cells, similar to how they would target viruses or bacteria. Although the immune system uses these checkpoints to protect healthy cells, cancer cells can manipulate this system to avoid detection. Immunotherapy drugs like nivolumab and ipilimumab are designed to block these checkpoints, making cancer cells more detectable to T cells.

However, more than a third of melanoma patients given checkpoint inhibitors develop side effects so severe that they compromise their quality of life and ability to continue therapy. Side effects most often involve some form of inflammation, a sign of an overactive immune response. Patients can experience severe skin rashes, diarrhea, or hyperthyroidism. More severe side effects can include liver toxicity, colitis, and rheumatoid arthritis.

In the new study, publishing in the journal Clinical Cancer Research, researchers found that even before treatment began in their test subjects, the activity of genes controlling the production of spleen tyrosine kinases predicted 83 percent of melanoma patients who eventually developed severe side effects from combined immunotherapy with nivolumab and ipilimumab.

Potential for Blood Test to Predict Severe Side Effects in Melanoma Immunotherapy

Moreover, the researchers found that this heightened gene signature, as evidenced by the production of Spleen Tyrosine Kinases or the SYK pathway, did not interfere with the effectiveness of therapies in preventing recurrence of melanoma. The impact was connected only to side effects.

“Our study results show that increased gene activity in the spleen tyrosine kinase pathway could be the basis of a possible blood test that identifies melanoma patients most susceptible to having severe side effects from immunotherapy, and well before they start treatment,” said study co-lead investigator Kelsey Monson, Ph.D.

“Predictive information of this kind is critically important to oncologists and patients to help guide their immunotherapy decisions, to either minimize these side effects by taking additional precautions or choose alternative immunotherapies,” said study co-senior investigator Tomas Kirchhoff, Ph.D. Kirchhoff is an associate professor in the Department of Population Health at NYU Grossman School of Medicine and a member of Perlmutter Cancer Center.

For the study, researchers analyzed immune system cell samples from 212 men and women with melanoma participating in a national multicenter trial called CheckMate-915. The trial was designed to test whether combined therapy with nivolumab and ipilimumab worked better than single therapy with nivolumab in preventing postsurgical recurrence of melanoma. All immune cell samples were taken prior to the start of immunotherapy. Both drugs are manufactured by the pharmaceutical company Bristol Myers Squibb, which sponsored the CheckMate-915 trial, and provided the patient specimens and data used in the analysis.

When researchers looked at what genes were more active than others in patients who experienced side effects from their immunotherapy, they found a specific pattern among 24 genes tied to the production of spleen tyrosine kinases. Further statistical analyses showed that increased or decreased activity (transcription) of only five of these genes — CD22, PAG1, CD33, HNRNPU, and FCGR2C — along with age and stage severity of their melanoma served as the best predictors of who would experience immunotherapy side effects.

Study co-senior investigator Jeffrey Weber, MD, Ph.D, says that the SYK pathway has previously been linked to other autoimmune diseases, including lupus, rheumatoid arthritis, and colitis, disorders marked by the immune system attacking healthy cells. He also points out that immunotherapy side effects were also most common in areas affected by these autoimmune diseases, including the skin, colon, and liver.

Weber, the Laura and Isaac Perlmutter Professor of Oncology in the Department of Medicine at NYU Grossman School of Medicine, says the team next plans to investigate if an activated SYK pathway is predictive of side effects in patients treated with ipilimumab alone or with other combination immunotherapies. Weber also serves as deputy director of NYU Langone’s Perlmutter Cancer Center.

“If our future research can explain how an activated spleen tyrosine kinase pathway leads to increased risk of side effects from immunotherapy, then it could also potentially help us to design better cancer immunotherapies and potentially other treatments for autoimmune diseases,” said Kirchhoff.

Reference:

1. Tyrosine-protein kinase SYK-related gene signature in baseline immune cells associated with adjuvant immunotherapy-induced immune-related adverse events in melanoma – (https://aacrjournals.org/clincancerres/article-abstract/doi/10.1158/1078-0432.CCR-24-0900/746832/Tyrosine-protein-kinase-SYK-related-gene-signature?redirectedFrom=fulltext)

Source-Eurekalert